PDF Archive

Easily share your PDF documents with your contacts, on the Web and Social Networks.

Share a file Manage my documents Convert Recover PDF Search Help Contact



cvfile 0023228 .pdf



Original filename: cvfile_0023228.pdf
Title: CURRICULUM VITAE
Author: TIMS

This PDF 1.5 document has been generated by Microsoft® Word 2010, and has been sent on pdf-archive.com on 10/05/2015 at 21:29, from IP address 31.11.x.x. The current document download page has been viewed 861 times.
File size: 215 KB (24 pages).
Privacy: public file




Download original PDF file









Document preview


CURRICULUM VITAE
(Last updated: 2013-04-12)
Young-Hyuck Im, M.D., PhD
Academic Training
Mar.1980 - Feb. 1984 : College of Medicine, Seoul National
University (Graduated with M.D. degree)
Mar.1991 - Feb. 1993 : Master Course in Internal Medicine,
Postgraduate School, Seoul National
University (Graduated with M.S. degree)
Mar.1994 - Feb. 1996 : Ph.D Course in Internal Medicine,
Postgraduate School, Seoul National
University (Graduated with Ph.D degree)
Clinical Experience
May 1987 - Feb. 1988
Mar. 1988 - Feb. 1991

Mar. 1991 - Jan. 1992
Jan. 1992 – Feb.1997

: Internship at Seoul National University
Hospital
: Resident in Department of Internal
Medicine, Seoul National University
Hospital
: Clinical Fellowship in Section of
Hematology/Oncology, Seoul National
University Hospital
: Chief, Section of Hematology/Oncology II,
Department of Internal Medicine, Korea
Cancer Center Hospital

Nov. 1997 – Feb. 2000 : Research Fellowship in National Cancer
Institute, National Institute of Health (NIH),
USA
Feb. 2000- Mar. 2004 : Assisstant professor, Sungkyunkwan University
School of Medicine, Department of Internal
Medicine, Division of Hematology/Medical
Oncology
April. 2004- Mar, 2010 : Associate professor, Sungkyunkwan University
School of Medicine, Department of Internal
Medicine, Division of Hematology/Medical
Oncology
April, 2010- present
: Professor, Sungkyunkwan University

Sep. 2005- Aug. 2009
Mar.2007 – Feb.2011
June, 2010 - present
Feb, 2010 – Nov.2011
Nov. 2011- present

Nov, 2011- Feb, 2013
Nov, 2011- present

School of Medicine, Department of Internal
Medicine, Division of Hematology/Medical
Oncology
: Chair, Breast Cancer Center, Samsung
Comprehensive Cancer Center
: Chair, Breast Cancer Subcommitte, Korea
Cancer Study Group(KCSG)
: Chair, Educational committee, Korean
Association for Clinical Oncology
: Director, Reserch planning & strategy, Office of
Biomedical Research
: Director, Clinical Research Institute, Research
Institute for Future Medicne, Samsung Medical
Center
: Associate Director, Samsung Comprehensive
Cancer Center
: Head, Division of Hematology/Oncology,
Samsung Medical Center

Licenced Qualification
Feb. 1984 : Passed Examination for the National Board of Medical
Licence, Korea
Feb. 1991 : Passed Examination for the National Board of Internal
Medicine, licenced as specialist in Internal Medicine
Nov. 1995 : Diplomate, Subspeciality in Hematology/Oncology
Membership in Professional Societies
Korea Medical Association
Korean Society of Internal Medicine
Korean Cancer Association
American Society of Clinical Oncology(ASCO)
American Society of Hematology(ASH)
European Society of Medical Oncology(ESMO)

Publications
1. Park YH, Jung KH, Im SA, Sohn JH, Ro J, Ahn JH, Kim SB, Nam BH,
Oh DY, Han SW, Lee S, Park IH, Lee KS, Kim JH, Kang SY, Lee MH,
Park HS, Ahn JS, Im YH. Phase III, Multicenter, Randomized Trial of
Maintenance Chemotherapy Versus Observation in Patients With
Metastatic Breast Cancer After Achieving Disease Control With Six
Cycles of Gemcitabine Plus Paclitaxel As First-Line Chemotherapy:
KCSG-BR07-02. J Clin Oncol. 2013 Apr 8. [Epub ahead of print]

2. Ko ES, Han BK, Kim RB, Ko EY, Shin JH, Hahn SY, Nam SJ, Lee JE,
Lee SK, Im YH, Park YH. Analysis of Factors that Influence the
Accuracy of Magnetic Resonance Imaging for Predicting Response after
Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. Ann
Surg Oncol. 2013 Mar 6. [Epub ahead of print]

3. Kim HR, Jung KH, Im SA, Im YH, Kang SY, Park KH, Lee S, Kim SB,
Lee KH, Ahn JS, Kim SI, Sohn JH. Multicentre phase II trial of
bevacizumab combined with docetaxel-carboplatin for the neoadjuvant
treatment of triple-negative breast cancer (KCSG BR-0905).Ann Oncol.
2013 Feb 8. [Epub ahead of print]

4. Ro J, Park S, Kim S, Kim TY, Im YH, Rha SY, Chung JS, Moon H,
Santillana S. Clinical outcomes of HER2-positive metastatic breast
cancer patients with brain metastasis treated with lapatinib and
capecitabine: an open-label expanded access study in Korea. BMC
Cancer. 2012 Jul 28;12:322.

5. Bae SH, Park W, Huh SJ, Choi DH, Nam SJ, Im YH, Ahn JS. Radiation
treatment in pathologic n0-n1 patients treated with neoadjuvant
chemotherapy followed by surgery for locally advanced breast cancer. J
Breast Cancer. 2012 Sep;15(3):329-36.

6. Park SY, Lim SY, Um SW, Koh WJ, Chung MP, Kim H, Kwon OJ, Park
HK, Kim SJ, Im YH, Ahn MJ, Suh GY. Outcome and predictors of
mortality in patients requiring invasive mechanical ventilation due to
acute respiratory failure while undergoing ambulatory chemotherapy for
solid cancers. Support Care Cancer. 2013 Jan 12. [Epub ahead of print]

7. Lee S, Cho EY, Park YH, Ahn JS, Im YH. Prognostic impact of FOXP3
expression in triple-negative breast cancer. Acta Oncol. 2013
Jan;52(1):73-81.

8. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini
JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM;
CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus
docetaxel for metastatic breast cancer. N Engl J Med. 2012 Jan
12;366(2):109-19
9. Ahn HK, Lee S, Park YH, Sohn JH, Jo JC, Ahn JH, Jung KH, Park S,
Cho EY, Lee JI, Park W, Choi DH, Huh SJ, Ahn JS, Kim SB, Im YH.
Prediction of outcomes for patients with brain parenchymal metastases
from breast cancer (BC): a new BC-specific prognostic model and a
nomogram. Neuro Oncol. 2012 Aug;14(8):1105-13
10. Ro J, Park S, Kim SB, Kim TY, Im YH, Rha SY, Chung JS, Moon H,
Santillana S. Clinical outcomes of HER2-positive metastatic breast
cancer patients with brain metastasis treated with lapatinib and
capecitabine: an open-label expanded access study in Korea. BMC
Cancer. 2012 Jul 28;12(1):322

11. Kwon MJ, Park S, Choi JY, Oh E, Kim YJ, Park YH, Cho EY, Kwon MJ,
Nam SJ, Im YH, Shin YK, Choi YL. Clinical significance of CD151
overexpression in subtypes of invasive breast cancer. Br J Cancer. 2012
Feb 28;106(5):923-30

12. Park YH, Im SA, Cho EY, Choi YL, Lee JE, Nam SJ, Yang JH, Ahn JS,
Im YH. Small node-negative (T1b-cN0) invasive hormone receptorpositive breast cancers: is there a subpopulation that might have benefit
from adjuvant chemotherapy? Breast Cancer Res Treat. 2012
May;133(1):247-55.
13. Park S, Ahn HK, Park LC, Hwang DW, Ji JH, Maeng CH, Cho SH, Lee
JY, Park KT, Ahn JS, Park YH, Im YH. Implications of different CA 15-3

levels according to breast cancer subtype at initial diagnosis of recurrent
or metastatic breast cancer. Oncology. 2012;82(3):180-7
14. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A,
Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B,
Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T,
Ratnayake J, Ross G, Valagussa P. Efficacy and safety of neoadjuvant
pertuzumab and trastuzumab in women with locally advanced,
inflammatory, or early HER2-positive breast cancer (NeoSphere): a
randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012
Jan;13(1):25-32.
15. Noh JM, Choi DH, Huh SJ, Park W, Yang JH, Nam SJ, Im YH, Ahn JS.
Patterns of recurrence after breast-conserving treatment for early stage
breast cancer by molecular subtype. J Breast Cancer. 2011
Mar;14(1):46-51
16. Kong JH, Park YH, Kim JA, Kim JH, Yun J, Sun JM, Won YW, Lee S,
Kim ST, Cho EY, Ahn JS, Im YH. Patterns of skin and soft tissue
metastases from breast cancer according to subtypes: relationship
between EGFR overexpression and skin manifestations. Oncology.
2011;81(1):55-62.
17. Im SA, Lee KS, Ro J, Lee ES, Kwon Y, Ahn JH, Ahn JS, Kim JH, Kang
HS, Shin KH, Noh DY, Park IA, Kim SB, Im YH, Ha SW. Phase II trial of
preoperative paclitaxel, gemcitabine, and trastuzumab combination
therapy in HER2 positive stage II/III breast cancer: the Korean Cancer
Study Group BR 07-01. Breast Cancer Res Treat. 2012 Apr;132(2):589600.

18. Lee SJ, Park S, Ahn HK, Yi JH, Cho EY, Sun JM, Lee JE, Nam SJ, Yang
JH, Park YH, Ahn JS, Im YH. Implications of bone-only metastases in
breast cancer: favorable preference with excellent outcomes of hormone
receptor positive breast cancer. Cancer Res Treat. 2011 Jun;43(2):89-95.
Epub 2011 Jun 30

19. Lee S, Ahn HK, Park YH, Nam DH, Lee JI, Park W, Choi DH, Huh SJ,
Park KT, Ahn JS, Im YH. Leptomeningeal metastases from breast
cancer: intrinsic subtypes may affect unique clinical manifestations.
Breast Cancer Res Treat. 2011 Oct;129(3):809-17

20. Park S, Jung HH, Park YH, Ahn JS, Im YH. ERK/MAPK pathways play
critical roles in EGFR ligands-induced MMP1 expression. Biochem
Biophys Res Commun. 2011 Apr 22;407(4):680-6.

21. Yun J, Kim KH, Kang ES, Gwak GY, Choi MS, Lee JE, Nam SJ, Yang
JH, Park YH, Ahn JS, Im YH. Prophylactic use of lamivudine for hepatitis
B exacerbation in post-operative breast cancer patients receiving
anthracycline-based adjuvant chemotherapy. Br J Cancer. 2011 Feb
15;104(4):559-63.

22. Park YH, Lee SJ, Cho EY, Choi YL, Lee JE, Nam SJ, Yang JH, Shin JH,
Ko EY, Han BK, Ahn JS, Im YH. Clinical relevance of TNM staging
system according to breast cancer subtypes. Ann Oncol. 2011
Jul;22(7):1554-60.

23. Jang S, Lee SH, Kim S, Lee YK, Im YH, Han W, Park HS. The
effectiveness of Silver In Situ hybridization in patients with breast cancer:
A systematic review. J of Breast Cancer. 2011 Feb; 14(S): S1-9

24. Lee SJ, Choi YL, Park YH, Kim ST, Cho EY, Ahn JS, Im YH.
Thymidylate synthase and thymidine phosphorylase as predictive
markers of capecitabine monotherapy in patients with anthracycline- and
taxane-pretreated metastatic breast cancer. Cancer Chemother
Pharmacol. 2010 Sep;68(3):743-51

25. Cho EY, Chang MH, Choi YL, Lee JE, Nam SJ, Yang JH, Park YH, Ahn
JS, Im YH. Potential candidate biomarkers for heterogeneity in triplenegative breast cancer (TNBC). Cancer Chemother Pharmacol. 2010
Sep;68(3):753-61.

26. Rhee J, Han SW, Cha Y, Ham HS, Kim HP, Oh DY, Im SA, Park JW, Ro
J, Lee KS, Park IH, Im YH, Bang YJ, Kim TY. High serum TGF-α

predicts poor response to lapatinib and capecitabine in HER2-positive
breast cancer. Breast Cancer Res Treat. 2011 Jan;125(1):107-14.

27. Kim JE, Ahn JH, Jung KH, Kim SB, Kim HJ, Lee KS, Ro JS, Park YH,
Ahn JS, Im YH, Im SA, Lee MH, Kim SY. Zoledronic acid prevents bone
loss in premenopausal women with early breast cancer undergoing
adjuvant chemotherapy: a phase III trial of the Korean Cancer Study
Group (KCSG-BR06-01). Breast Cancer Res Treat. 2011 Jan;125(1):99106.

28. Choi YL, Oh E, Park S, Kim Y, Park YH, Song K, Cho EY, Hong YC,
Choi JS, Lee JE, Kim JH, Nam SJ, Im YH, Yang JH, Shin YK. Triplenegative, basal-like, and quintuple-negative breast cancers: better
prediction model for survival. BMC Cancer. 2010 Sep 23;10:507.
Erratum in: BMC Cancer. 2011;11:13.

29. Choi MK, Park YH, Hong JY, Park HC, Ahn YC, Kim K, Shim YM, Kang
WK, Park K, Im YH. Clinical implications of esophagorespiratory fistulae
in patients with esophageal squamous cell carcinoma (SCCA). Med
Oncol. 2010 Dec;27(4):1234-8.

30. Yi SY, Ahn JS, Uhm JE, Lim DH, Ji SH, Jun HJ, Kim KH, Chang MH,
Park MJ, Cho EY, Choi YL, Park YH, Im YH. Favorable response to
doxorubicin combination chemotherapy does not yield good clinical
outcome in patients with metastatic breast cancer with triple-negative
phenotype. BMC Cancer. 2010 Oct 5;10(1):527
31. Bae SH, Park W, Huh SJ, Choi DH, Nam H, Yang JH, Nam SJ, Lee JE,
Im YH, Ahn JS, Park YH. Result of neoadjuvant chemotherapy, surgery
and radiation therapy in locally advanced breast cancer. J Kor Soc Ther
Radiol Oncol 2010 28(2):71-78
32. Park HJ, Koo YA, Im YH, Yoon BK, Choi D.GnRH agonist therapy to
protect ovarian function in young Korean breast cancer patients. J
Korean Med Sci. 2010 Jan;25(1):110-6.
33. Park YH, Lee S, Cho EY, Choi YL, Lee JE, Nam SJ, Yang JH, Ahn JS,
Im YH. Patterns of relapse and metastatic spread in HER2-

overexpressing breast cancer according to estrogen receptor status.
Cancer Chemother Pharmacol. 2010 Aug;66(3):507-16
34. Jung HH, Park YH, Jun HJ, Kong J, Kim JH, Kim JA, Yun J, Sun JM,
Won YW, Lee S, Kim ST, Ahn JS, Im YH. Matrix metalloproteinase-1
expression can be upregulated through mitogen-activated protein kinase
pathway under the influence of human epidermal growth factor receptor
2 synergized with estrogen receptor. Mol Cancer Res. 2010
Jul;8(7):1037-47
35. Lee S, Park YH, Kim KH, Cho EY, Ahn YC, Kim K, Shim YM, Ahn JS,
Park K, Im YH. Thymidine synthase, thymidine phosphorylase, and
excision repair cross-complementation group 1 expression as predictive
markers of capecitabine plus cisplatin chemotherapy as first-line
treatment for patients with advanced oesophageal squamous cell
carcinoma. Br J Cancer. 2010 Sep 7;103(6):845-51
36. Park YH, Kim ST, Cho EY, Choi YL, Ok ON, Baek HJ, Lee JE, Nam SJ,
Yang JH, Park W, Choi DH, Huh SJ, Ahn JS, Im YH. A risk stratification
by hormonal receptors (ER, PgR) and HER-2 status in small (< or = 1
cm) invasive breast cancer: who might be possible candidates for
adjuvant treatment? Breast Cancer Res Treat. 2010 Feb;119(3):653-61.
37. Choi JH, Lim HI, Lee SK, Kim WW, Kim SM, Cho E, Ko EY, Han BK,
Park YH, Ahn JS, Im YH, Lee JE, Yang JH, Nam SJ. The role of PET
CT to evaluate the response to neoadjuvant chemotherapy in advanced
breast cancer: Comparison with ultrasonography and magnetic
resonance imaging. J Surg Oncol. 2010 Oct 1;102(5):392-397
38. Kim HS, Park YH, Park MJ, Chang MH, Jun HJ, Kim KH, Ahn JS, Kang
WK, Park K, Im YH. Clinical significance of a serum CA15-3 surge and
the usefulness of CA15-3 kinetics in monitoring chemotherapy response
in patients with metastatic breast cancer. Breast Cancer Res Treat. 2009;
118(1):89-97
39. Park YH, Park MJ, Ji SH, Yi SY, Lim DH, Nam DH, Lee JI, Park W, Choi
DH, Huh SJ, Ahn JS, Kang WK, Park K, Im YH. Trastuzumab treatment
improves brain metastasis outcomes through control and durable
prolongation of systemic extracranial disease in HER2-overexpressing
breast cancer patients. Br J Cancer. 2009 Mar 24;100(6):894-900.
40. Uhm JE, Park YH, Yi SY, Cho EY, Choi YL, Lee SJ, Park MJ, Lee SH,
Jun HJ, Ahn JS, Kang WK, Park K, Im YH. Treatment outcomes and
clinicopathologic characteristics of triple-negative breast cancer patients

who received platinum-containing chemotherapy. Int J Cancer. 2009 Mar
15;124(6):1457-62.
41. Park BB, Uhm JE, Cho EY, Choi YL, Ji SH, Nam do H, Il Lee J, Park W,
Huh SJ, Park YH, Ahn JS, Im YH. Prognostic factor analysis in patients
with brain metastases from breast cancer: how can we improve the
treatment
outcomes?
Cancer
Chemother
Pharmacol.
2009
Mar;63(4):627-33.
42. Lee SG, Jee YG, Chung HC, Kim SB, Ro J, Im YH, Im SA, Seo JH.
Cost-effectiveness analysis of adjuvant therapy for node positive breast
cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC)
versus fluorouracil, doxorubicin and cyclophosphamide (FAC). Breast
Cancer Res Treat. 2009 Apr;114(3):589-95.
43. Park YH, Jung HH, Ahn JS, Im YH. Ets-1 upregulates HER2-induced
MMP-1 expression in breast cancer cells. Biochem Biophys Res
Commun. 2008 Dec 12;377(2):389-94.
44. Lee J, Im YH, Lee SH, Cho EY, Choi YL, Ko YH, Kim JH, Nam SJ, Kim
HJ, Ahn JS, Park YS, Lim HY, Han BK, Yang JH. Evaluation of ER and
Ki-67 proliferation index as prognostic factors for survival following
neoadjuvant chemotherapy with doxorubicin/docetaxel for locally
advanced breast cancer. Cancer Chemother Pharmacol. 2008
Apr;61(4):569-77.
45. Louis C, Im YH. Current treatment of locally advanced and metastatic
breast cancer in the Asia-Pacific region: Challenges and limitations.
Asia-Pacific J Clin Oncol 2008; 4(Suppl. 3):S14-23
46. Lee J, Im YH, Cho EY, Hong YS, Lee HR, Kim HS, Kim MJ, Kim K,
Kang WK, Park K, Shim YM. A phase II study of capecitabine and
cisplatin (XP) as first-line chemotherapy in patients with advanced
esophageal squamous cell carcinoma. Cancer Chemother Pharmacol.
2008 Jun;62(1):77-84. Epub 2007 Aug 31

47. Kim H, Huh SJ, Park W, Choi DH, Kang MK, Yang JH, Nam SJ, Im YH.
Results of three-dimensional conformational radiation therapy for the
treatment of a solitary sternal relapse of breast cancer. J Koraen Soc
Thera Radiol Oncol 2008; 26(2):91-95


Related documents


v15n4s57revisiting
palimo recommendations 2017 final v2
luca gianni
contribution of chemotherapy to 5 year survival
310812900 final announcement roicam 4
quality cancer care maui judy l schmidt md facp


Related keywords